Levetiracetam (Keppra(R)), developed by UCB, was approved in the U.S. in 1999 as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. It is also approved in several European countries. Lundbeck holds marketing rights to the drug in Canada, where it is under review by the regulatory authorities (1). The drug is also under evaluation for the treatment of neuropathic pain and migraine.
机构:
CHU Lille, Ctr Reg Pharmacovigilance Nord Pas de Calais, F-59000 Lille, France
Univ Lille 2, U1171, F-59000 Lille, France
INSERM, U1171, F-59000 Lille, FranceCtr Hosp Lens, Serv Pharm, F-62300 Lens, France
Gautier, Sophie
Bene, Johana
论文数: 0引用数: 0
h-index: 0
机构:
CHU Lille, Ctr Reg Pharmacovigilance Nord Pas de Calais, F-59000 Lille, France
Univ Lille 2, U1171, F-59000 Lille, France
INSERM, U1171, F-59000 Lille, FranceCtr Hosp Lens, Serv Pharm, F-62300 Lens, France
机构:
Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, WarsawInstitute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, Warsaw
Narczyk A.
Mrozowicz M.
论文数: 0引用数: 0
h-index: 0
机构:
Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, WarsawInstitute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, Warsaw
Mrozowicz M.
Stecko S.
论文数: 0引用数: 0
h-index: 0
机构:
Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, WarsawInstitute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, Warsaw
机构:Institute of Neurology/The National Hospital for Neurology and Neurosurgery,Pharmacology and Therapeutics Unit, Department of Clinical and Experimental Epilepsy